Facebook Twitter YouTube Google Plus

D.) Fundraising

Ann Abbe, Member
Board of Directors
Mesothelioma Applied Research Foundation

Ann Abbe has been a nonprofit professional for 30 years, and is the Vice President for Development at the University of North Texas. She is an expert in fundraising and helping nonprofits reach their highest potential through strategic planning and effective organization. She brings to us all of this professional expertise, and also a personal passion for the Foundation and our mission. Ann knows first-hand the urgency of the need to eradicate mesothelioma, several years ago she lost her brother, Mike Melton, to the disease.

University of North Texas
Denton, Texas

Click here to view the slides for "Fundraising" by Ann Abbe.

To view the video presentation, please click on the image below.

© 2009 Mesothelioma Applied Research Foundation, Inc. All rights reserved. 501(c)(3)

A.) Effective Advocacy and the Case for Federal Meso Research Funding

B.) State Assistance on Insurance Appeals

C.) Cancer Genetics in the Mesothelioma Family

D.) Fundraising

E.) Navigating Mesothelioma Clinical Trials with GPS (Getting Personalized Service)

F.) Update from Across the Pond

G.) The Mesothelioma Experience: Patient and Provider Perspectives Panel

H.) Work of the Science Advisory Board

J.) Present and Future of Mesothelioma Treatment: Medical Oncologist and Researcher Perspective

K.) New Developments in Radiation Oncology: A Global Perspective

M.) Pain Management

Mesothelioma Treatment: Present & Future from a Surgeon & Research Perspective | Dr. Harvey Pass

N.) Traditional Healing with Modern Science

O.) Update on Clinical Trials and Mesothelioma Research

P.) Mesothelioma Tissue Bank

Photodynamic Therapy for Mesothelioma Treatment | Dr. Joseph Friedberg

Q.) EGFR Inhibitors for Patients with Malignant Peritoneal Mesothelioma

R.) The Use of Cytokine Inhibitors: Translational Lab Results

S.) Identifying and Targeting Aggressive Malignant Peritoneal Mesothelioma: Morphologic and Molecular Studies

T.) Treatment Options for Patients with Recurrent Disease after HIPEC, HRA - Panel Discussion